Results 101 to 110 of about 19,166 (184)

The complement factsbook /

, 2000
The Complement FactsBook contains entries on all components of the Complement System, including C1q and Lectins, C3 Family, Serine Proteases, Serum Regulators of Complement Activation, Cell Surface Proteins, and Terminal Pathway Proteins.
Morley, Bernard J., Walport, Mark.
core  

Data_Sheet_1_A Single-Domain Antibody Targeting Complement Component C5 Acts as a Selective Inhibitor of the Terminal Pathway of the Complement System and Thus Functionally Mimicks the C-Terminal Domain of the Staphylococcus aureus SSL7 Protein.pdf

, 2018
The complement system is an efficient anti-microbial effector mechanism. On the other hand abnormal complement activation is involved in the pathogenesis of multiple inflammatory and hemolytic diseases.
Niels Anton Friis (467949), Steffen Thiel (12664), Jakob A. Østergaard (6020366), Laure Yatime (3471635), Lubka T. Roumenina (5809328), Peter Kristensen (467952), Mette Bjerre (5049605), Nicolas S. Merle (6020360), Annette G. Hansen (6020363), Gregers R. Andersen (764438)   +9 more
core   +1 more source

Streptococcus pneumoniae phosphoglycerate kinase is a novel complement inhibitor affecting the membrane attack complex formation.

, 2014
The Gram-positive bacterium Streptococcus pneumoniae is a major human pathogen that causes infections ranging from acute otitis media to life-threatening invasive disease. Pneumococci have evolved several strategies to circumvent the host immune response,
Blom, Anna, Anna M. Blom, Vaibhav Agarwal, Marcus Fulde, Fulde, Marcus, Simone Bergmann, Agarwal, Vaibhav, Bergmann, Simone, Riesbeck, Kristian, Kristian Riesbeck   +9 more
core   +1 more source

Paroxysmal Nocturnal Hemoglobinuria: Unraveling Its Molecular Pathogenesis and Advancing Targeted Therapeutic Strategies

Diseases
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired clonal hematologic disorder caused by somatic mutations in the PIGA gene of hematopoietic stem cells, leading to the absence of GPI-anchored proteins, including the complement regulators CD55 ...
Elisavet Apostolidou, Vasileios Georgoulis, Dimitrios Leonardos, Eleni Kapsali, Eleftheria Hatzimichael   +4 more
doaj   +1 more source

On the value of therapeutic interventions targeting the complement system in acute myocardial infarction

, 2017
The complement system plays an important role in the inflammatory response subsequent to acute myocardial infarction (AMI). The aim of this study is to create a systematic overview of studies that have investigated therapeutic administration of ...
Hans W.M. Niessen, Reindert W. Emmens, S. Marieke van Ham, Niessen, Hans W. M., Sacha Zeerleder, Paul A.J. Krijnen, Krijnen, Paul A J, van Ham, S Marieke, van Ham, S. Marieke, Krijnen, Paul A. J., Emmens, Reindert W, Wouters, Diana, Zeerleder, Sacha, Emmens, Reindert W., Diana Wouters, Niessen, Hans W M   +15 more
core   +1 more source

Outcome of atypical hemolytic uremic syndrome: role of triggers and complement abnormalities in the response to C5 inhibition

Background Atypical-hemolytic uremic syndrome (aHUS) is a rare thrombotic microangiopathy often due to uncontrolled complement activation, characterized by high risk of end-stage kidney disease (ESKD).
Luca F., Marco D., Ardissino G., Fabian S., Leonardo P., Marco M., Porcaro L., Doriana C., Angelo F., Giuseppe S., Silvia T., Mancuso M. C., Alessandro I., Tiziana S., Cristina M., Nicola M., Alessandra B., Vera P., Donatella C., Francesco O., Paola S., Lorenza M., Luca V., Andrea R., Florjan M., Cresseri D., Silvio M., Alessandro A., Roberta F., Alessandra C., Maria F., Laura T., Aristide T., Barbara R., Andrea G., Chiara S., Amico V., Philippis D., Luigia C., Valeria C., Carlo A., Domenico F., Vecchio D., Barbara A., Roberto R., Verna M., Alessandro B., Maria N., Carmelita M., Olga C., Pellu V., Capone V., Laura S., Chiara T., Rita M., Griffini S., Cugno M., Lucrezia F., Nicola C., Lorella T., Andrea P., Alessandra M., Enrico M., Giacomo C., Bruno B., Alessandro C., Fabio G., Evangeline R., Enrico V., Delia D., Francesco T., Tommaso M., Giovanni G., Teresa R., Ilaria P., Nunzia D., Monica T., Angelo R., Martina T., Riccardo F., Tangredi M., Francesco C., Fabio P., Jacopo P., Rodolfo R., Sarah M., Grovetti E., Marta V., Sara T., Giulia P., Domenico M., Maurizio B., Castellano G., Ciro C., Brigida B., Giuseppe P., Simona V., Lucia P., Gianmarco P., Laura M., Paolo V., Maria B., Montini G., Elisabetta T., Alessandro N., Werner P., Francesco I., Gina G., Alice A., Karen A., Biase D., Scola L., Sabrina M., Selena L., Giorgio P., Concetta M., Aldo C., Valentina N., Calogero C., Marco Z., Leonardo C., Antonello P., Jacopo M., Annunziata M., Consonni D., Mario G., Raffaella C., Giuseppe V.   +127 more
core   +1 more source

Corrigendum: Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation

Frontiers in Immunology, 2023
Guo-Qing Tang, Yalan Tang, Ketki Dhamnaskar, Michelle D. Hoarty, Rohit Vyasamneni, Douangsone D. Vadysirisack, Zhong Ma, Nanqun Zhu, Jian-Guo Wang, Charlie Bu, Bestine Cong, Elizabeth Palmer, Petra W. Duda, Camil Sayegh, Alonso Ricardo   +14 more
doaj   +1 more source

Discovery of Zilucoplan: A Complement C5 Inhibitor for Treatment of Anti-Acetylcholine Receptor (AChR) Antibody-Positive Generalized Myasthenia Gravis (gMG). [PDF]

J Med Chem
Ye P, Hammer RP, Wang Z, Dhamnaskar K, Hoarty M, Ma Z, Tang GQ, DeMarco SJ, Ricardo A.   +8 more
europepmc   +1 more source

Complement C5 inhibition in generalized myasthenia gravis is associated with improved survival and increased cardiovascular risk. [PDF]

Front Immunol
Vahldieck C, Fels B.
europepmc   +1 more source

Complement C5 inhibitors as add-on rescue treatment in severe AQP4-antibody neuromyelitis optica spectrum disorder attacks: a case series and literature review. [PDF]

Ther Adv Neurol Disord
Gan KX, Abu Hassan SHB, Tan XL, Li KZ, Thirugnanam U, Yeo T.   +5 more
europepmc   +1 more source